News
CNSP
5.11
+3.63%
0.18
Weekly Report: what happened at CNSP last week (0914-0918)?
Weekly Report · 09/21 10:13
Weekly Report: what happened at CNSP last week (0907-0911)?
Weekly Report · 09/14 10:18
Weekly Report: what happened at CNSP last week (0831-0904)?
Weekly Report · 09/07 10:12
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 09/02 12:07
CNS Pharmaceuticals details business development strategy
TipRanks · 09/01 13:20
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
Barchart · 09/01 08:01
Weekly Report: what happened at CNSP last week (0824-0828)?
Weekly Report · 08/31 10:19
Why Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories
NASDAQ · 08/29 10:34
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
Barchart · 08/27 08:01
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
Barchart · 08/27 08:01
Weekly Report: what happened at CNSP last week (0817-0821)?
Weekly Report · 08/24 10:19
Insider Move at CNS Pharmaceuticals Sparks Investor Buzz
TipRanks · 08/19 02:12
CNSP Q2 Loss Widens As $22.5M Financing Fuels Strategic Pipeline Pivot
NASDAQ · 08/18 17:57
Weekly Report: what happened at CNSP last week (0810-0814)?
Weekly Report · 08/17 10:20
CNS Pharmaceuticals reports Q2 EPS (37c) vs. ($6.42) last year
TipRanks · 08/17 09:41
CNS Pharmaceuticals GAAP EPS of -$0.37 misses by $0.13
Seeking Alpha · 08/12 12:05
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
Barchart · 08/12 07:00
Weekly Report: what happened at CNSP last week (0803-0807)?
Weekly Report · 08/10 10:15
Weekly Report: what happened at CNSP last week (0727-0731)?
Weekly Report · 08/03 10:15
Weekly Report: what happened at CNSP last week (0720-0724)?
Weekly Report · 07/27 10:19
More
Webull provides a variety of real-time CNSP stock news. You can receive the latest news about CNS Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About CNSP
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.